Nov 16, 2012 posted by: admin
Drugmaker GlaxoSmithKline will pay Delaware $1.2 million and make changes to its drug marketing practices as part of an agreement to settle allegations that the company illegally marketed its diabetes drug Avandia.
The payment to Delaware is part of a settlement with Attorney General Beau Biden and 37 other Attorneys General in which GlaxoSmithKline will pay a total of $90 million to the states.
The Attorneys General allege that GlaxoSmithKline engaged in unfair and deceptive practices in promoting Avandia to doctors and other healthcare professionals. Specifically, the states allege that GlaxoSmithKline claimed that the drug had a positive cholesterol profile when, in fact, the company did not possess competent and reliable scientific evidence to substantiate the claim.